Diagnosis and management of pulmonary arterial hypertension

Jeanne Houtchens, Douglas Martin, James R Klinger, Jeanne Houtchens, Douglas Martin, James R Klinger

Abstract

Pulmonary arterial hypertension is a rare disease, which requires a high index of suspicion to diagnose when patients initially present. Initial symptoms can be nonspecific and include complaints such as fatigue and mild dyspnea. Once the disease is suspected, echocardiography is used to estimate the pulmonary arterial (PA) pressure and to exclude secondary causes of elevated PA pressures such as left heart disease. Right heart catheterization with vasodilator challenge is critical to the proper assessment of pulmonary hemodynamics and to determine whether patients are likely to benefit from vasodilator therapy. Pathologically, the disease is characterized by deleterious remodeling of the distal pulmonary arterial and arteriolar circulation, which results in increased pulmonary vascular resistance. In the last fifteen years, medications from three different classes have been approved for the treatment of pulmonary arterial hypertension. These include the prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Adapted from [55].

References

    1. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. Journal of the American College of Cardiology. 2009;54(1) supplement 1:S3–S9.
    1. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Annals of Internal Medicine. 1991;115(5):343–349.
    1. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics. 2000;67(3):737–744.
    1. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH consortium. Nature Genetics. 2000;26(1):81–84.
    1. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. The New England Journal of Medicine. 1992;327(2):70–75.
    1. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine. 1993;328(24):1732–1739.
    1. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120(5):1562–1569.
    1. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine. 1995;333(4):214–221.
    1. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax. 1997;52(12):1051–1055.
    1. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. American Journal of Physiology. 1998;275(5):L931–L941.
    1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 2009;54(1) supplement 1:S43–S54.
    1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. American Journal of Respiratory and Critical Care Medicine. 2006;173(9):1023–1030.
    1. Peacock AJ, Murphy NF, McMurrey JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal. 2007;30(1):104–109.
    1. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137(2):376–387.
    1. Bull TM. Physical exam in pulmonary arterial hypertension. Advances in Pulmonary Hypertension. 2005;4:6–10.
    1. Leuchte HH, Holzapel M, Baumgartner RA, et al. Clinical significance of brain natriurectic peptide in primary pulmonary hypertension. Journal of the American College of Cardiology. 2004;43(5):764–770.
    1. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2008;177(12):1364–1369.
    1. Bossone E, Citro R, Blasi F, Allegra L. Echocardiography in pulmonary arterial hypertension: an essential tool. Chest. 2007;131(2):339–341.
    1. Arcasoy SM, Christie JD, Ferrare VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. American Journal of Respiratory and Critical Care Medicine. 2003;167(5):735–740.
    1. Hinderliter AL, Willis PW, IV, Long W, et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH study group. Primary pulmonary hypertension. American Journal of Cardiology. 1999;84(4):481–484.
    1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents. Journal of the American College of Cardiology. 2009;53(17):1573–1619.
    1. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. The New England Journal of Medicine. 1992;327(2):76–81.
    1. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111.
    1. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Critical Care Medicine. 2001;29(5):1000–1005.
    1. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104(11):1218–1222.
    1. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105(20):2398–2403.
    1. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. The New England Journal of Medicine. 2005;353(20):2148–2157.
    1. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903.
    1. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2008;31(4):891–901.
    1. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin) British Heart Journal. 1987;57(3):270–278.
    1. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol) Annals of Internal Medicine. 1990;112(7):485–491.
    1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine. 1996;334(5):296–301.
    1. Menon N, McAlpine L, Peacock AJ, Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis and Rheumatism. 1998;41(3):466–469.
    1. Humbert M, Sanchez O, Fartoukh M, et al. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin) Chest. 1998;114, supplement 1:80S–82S.
    1. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Annals of Internal Medicine. 2000;132(6):425–434.
    1. McLaughlin VV, Barst RJ, Rich S, et al. Efficacy and safety of UT-15, a prostacyclin analogue for primary pulmonary hypertension. European Heart Journal. 1990;20:p. 486.
    1. Gaine SP, Oudiz R, Rich S. Acute hemodynamic effects of 15AU81, a stable prostacyclin analogue, in severe primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. 1998;157:p. A595.
    1. Simonneau G, Barst RJ, Galie N. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2002;165(6):800–804.
    1. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. 2005;172(12):1586–1589.
    1. Olschewski H, Simonneau G, Galie N. Inhaled iloprost for severe pulmonary hypertension. The New England Journal of Medicine. 2002;347(5):22–29.
    1. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. Journal of the American College of Cardiology. 2006;48(8):1672–1681.
    1. Voswinckel R, Ghofrani HA, et al. Inhaled treprostinil for treatment of chronic pulmonary arterial hypertension. Annals of Internal Medicine. 2006;144(2):149–150.
    1. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology. 2010;55(18):1915–1922.
    1. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. American journal of physiology. 1985;248(5):C550–C556.
    1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.
    1. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. The Lancet. 2001;358(9288):1119–1123.
    1. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. The New England Journal of Medicine. 2002;346(12):896–903.
    1. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation. 2008;117(23):3010–3019.
    1. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine. 2005;171(11):1292–1297.
    1. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009;54(1) supplement 1:S78–S84.
    1. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine. 2008;149(8):521–530.
    1. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: breath-2. European Respiratory Journal. 2004;24(3):353–359.
    1. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2006;174(11):1257–1263.
    1. A study of first line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) .
    1. Badesch. ACCP clinical practice guidelines. Chest. 2004;126S:35S–62S.
    1. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114(3):787–792.
    1. Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest. 2001;120(5):1547–1555.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe